Company intelligence / Profile preview

NovoCure

Ownership: Public · NVCR
Employees: ~1300
Development stage: Other

Overview

Novocure’s Tumor Treating Fields have demonstrated significant clinical benefit in aggressive cancers. In metastatic NSCLC, the pivotal phase III LUNAR trial showed median overall survival improvement from 9.9 to 13.2 months when added to standard therapies—marking the first substantial advance in this setting in over eight years. The therapy is generally well-tolerated with mostly low-grade skin side effects under adhesive arrays.

Therapeutic areas: Oncology
Modalities: Tumor Treating Fields (TTFields) – a non-invasive electric field-based therapy delivered via wearable devicesMedical device-based cancer therapy
Industry: Therapeutic Medical Devices

Partnerships

Merck/MSD for combination studies with KEYTRUDA® in NSCLC and glioblastoma

Financials

Market cap: $1.6B
Total revenue: $655.4M
Enterprise value: $1.4B

Beyond the preview

Go deeper on NovoCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoCure.